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Abstract 
Review on Extranodal NK/T-cell lymphoma and the 
genes involved. 
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Clinics and pathology 
Disease 
Peripheral T cell lymphomas (PTCL) are a 
heterogeneous group of aggressive neoplasm in 
adults. Among these are: peripheral T cell 
lymphoma, anaplastic large cell lymphoma, 
angioimmunoblastic T cell lymphoma, extranodal 
NK/T cell lymphoma (nasal type), enteropathy 
associated T cell lymphoma, hepatosplenic T cell 
lymphoma. Extranodal natural killer/T-cell 
lymphoma, nasal type (ENKL), or nasal NK/T cell 
lymphoma (angiocentric lymphoma), is an 
aggressive pathology, with predilection for Asian 
and South American populations (Barrionuevo C et 
al., 2007; Liang R et al., 2009). Neoplastic cells are 
surface CD3-, cytoplasmic CD3ε+, CD56+, 
cytotoxic-molecule positive, Epstein-Barr virus 
(EBV) positive, with germline T-cell receptor gene 
(Chan JK et al., 2008). This lymphoma is almost 
exclusively extranodal (Kwong YL et al., 2005). 
Occur commonly in the nasal and upper 
aerodigestive region. Occasional cases present in the 
skin, salivary gland, testis, and gastrointestinal tract. 
Quantification of circulating EBV DNA is an 
accurate biomarker of tumor load (Au WY et al., 
2005). Concomitant sequential chemotherapy and 
radiotherapy is standard treatment. 
Etiology 
Etiology is poorly understood, but is related in part 
to infection of the tumor cells with Epstein-Barr 
virus (EBV). Expression of EBV latent membrane 
protein-1 by immunohistochemistry has also been 
described (Kanavaros P et al., 1993). 
Epidemiology 
NK/T-cell lymphomas occur worldwide, with a 
strong geographic predilection for Asian population 
(China, Japan, Korea and Southeast Asia) and for 
Central and South American population (Mexico, 
Peru, Argentina and Brazil) (Kwong YL et al., 
2005).  
Constituting 5-15% of lymphomas in these countries 
(Swerdlow SH et al., 2016).  
The median age at presentation is 52 years (Au WY 
et al., 2009); however, rare cases have been reported 
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in childhood. There is a male predominance with an 
approximately 2:1 male to female ratio. (Chim SC et 
al., 2004; Li XY et al., 2009). 
Clinics 
The large majority of patients present with localized 
disease resulting in symptoms of nasal obstruction, 
epistaxis, and/or a destructive mass involving the 
nose, sinuses, or palate (Liu QF et al., 2014). Other 
extranodal sites may be involved either primarily 
(extranasal NK/T cell lymphoma) or as a direct 
extension of the primary tumor. These sites include 
the upper airway, Waldeyer's ring, gastrointestinal 
tract, skin, testis, lung, eye, or soft tissue (Tse E et 
al., 2013). Lymph nodes may be involved 
secondarily, but are only rarely the primary site of 
involvement. Bone marrow involvement and B 
symptoms are seen in approximately 10 and 35 
percent of patients, respectively (Li YX et al., 2009).  
Disease 
Diagnosis: The diagnosis of ENKL is made based 
upon the evaluation of a biopsy specimen from the 
site of involvement, usually in the facial area. 
Because the morphology of the tumor cells is so 
variable, it is important to consider this diagnosis in 
all cases of aggressive extranodal lymphoma 
associated with vascular invasion and necrosis.  
The key diagnostic features are the demonstration of 
NK/T cell markers and Epstein Barr virus (EBV). 
Although CD56 is typically expressed, tumors that 
do not express CD56 may still be classified as ENKL 
if both cytotoxic molecules and EBV are positive 
(Chan JK et al., 2008).  
Immunophenotype in this case can be useful; these 
tumors express CD2, cytoplasmic CD3, CD56, and 
cytotoxic granule proteins (Chan JK et al., 2008). 
Cytology 
Immunephenotype is similar to that of a NK cell. The 
atypical cells in most cases express CD2, CD56, and 
cytoplasmic CD3, but do not express surface CD3. 
Most cases express cytotoxic granule protein such as 
granzyme B, TIA-1, and perforin, and lack surface T 
cell receptor (TCR). Uncommon cases may express 
CD4, CD8, and/or CD7. (Lei KI et al., 2002). 
Pathology 
The tumors cells can be of any size, but most 
commonly are either medium-sized or a mixture of 
small and large cells. They have a moderate amount 
of pale/clear cytoplasm with irregularly folded 
nuclei typically containing granular chromatin and 
inconspicuous or small nucleoli. Azurophilic 
granules may be seen on touch preps stained with 
giemsa (Swerdlow SH et al., 2008). 
Treatment 
Therapy and prognosis are based upon the stage of 
the disease. In localized stages, combined modality 
therapy is the frequent treatment option (i.e., 
radiotherapy with concurrent chemotherapy) (Tse E 
et al., 2012). Radiation dose of 50 GY and 
concurrent therapy with reduced dose 2/3DeVIC 
(dexamethasone, etoposide, ifosfamide, carboplatin) 
or VIDL (etoposide, ifosfamide, dexamethasone, L-
asparaginase).  
CHOP-based regimen (cyclophosphamide, 
doxorubicin, vincristine and prednisone) is not 
recommended for NK/T-cell lymphoma (Kim SJ et 
al., 2010). 
Other chemotherapy regimens like LVP (L-
asparaginase, vincristine and prednisolone) or 
GELOX (gemcitabine, E. coli L-asparaginase, 
oxaplatin) are been used in this pathology with high 
rates of remissions.  
In disseminated disease cases, SMILE regimen 
(dexamethasone, methotrexate, ifosfomide, L-
asparaginase) achieves best results, but neutropenia 
occurred in most of the patients with high rates of 
serious infections (Kwong YL et al., 2012).  
The use of hematopoietic stem cell transplantation 
(HSCT) has been explored in NK/T-cell lymphomas, 
however most studies contained small number of 
patients so the results are difficult to interpret. 
Prognosis 
ENKL is an aggressive lymphoma. Without 
treatment survival is measured in months. The 
prognosis with treatment is largely related to the 
location and stage of disease at diagnosis.  
Age over 60 years, stage III/IV disease, distant 
lymph node involvement, non-nasal type and 
detectable Epstein-Barr virus viral DNA titer are 
consider the most important patient information for 
the prognosis determination. 
Genetics 
Note 
A high percentage of these tumors overexpress the 
p53 tumor suppressor protein, with about one-
quarter showing evidence of p53 mutation 
(Quintanilla-Martinez L et al., 2001). In most other 
tumor types, p21 overexpression is linked to wild-
type p53 expression, but in this tumor it has been 
found even with mutant p53 or low p53 expression. 
Other tumor suppressor genes that have been 
implicated in the pathogenesis of ENKL include 
PRDM1 and FOXO3 (Karube et al., 2011). The gene 
PRDM1 (alias BLIMP1) is particularly interesting 
because it regulates the amduration, homeostasis and 
proliferation of NK cells (Kallies A et al., 2011).  
Several oncogenic pathways are activated, including 
Notch-1, Wnt, JAK/STAT, AKT, and nuclear factor 
kB. Recently, hole-exome sequencing has identified 
somatic-activating mutations of the JAK3 gene in 
35% of NK/T-cell lymphomas (Koo GC et al., 2012) 
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The TCR and immunoglobulin (Ig) genes are usually 
germline, but a small fraction of cases demonstrate 
clonal rearrangement of TCR genes, suggesting 
derivation from a cytotoxic T lymphocyte (Lipford 
et al., 1988). Clonal EBV genomes are virtually 
always present. In situ hybridization for EVB 
encoded small nuclear RNAs is the preferred method 
of demonstrating the presence of EBV (Lei KL et al, 
2002). 
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